Karyopharm Therapeutics Inc. (NASDAQ: KPTI) is a healthcare company, listed on the NASDAQ. Alpha Stocks Insight has published 2 articles on KPTI since May 14, 2026, most recently "Karyopharm (KPTI) Q2 2026: EPS Misses by 78%, Cash Runway Extends Only to September" on Friday, August 14, 2026. Coverage to date spans Earnings Report, tracking KPTI's earnings, analyst activity, and material corporate events. New coverage is added each trading day.
KPTI posted a GAAP EPS loss of $2.32 vs. the $1.30 consensus estimate, and cash runs out in September without new financing.
Karyopharm beat Q1 2026 revenue estimates, completed enrollment in its Phase 3 endometrial cancer trial, and landed a late-breaking ASCO oral presentation slot.
Important Legal Disclaimer
This is for informational purposes only and is not financial, investment, or tax advice. Past performance is no guarantee of future results. We are not licensed advisors. For Swiss residents: This does not constitute a public offer under FINSA. For EU residents: Not MiFID II compliant advice. For US residents: Not SEC-registered advice. Always consult a qualified professional. Investing involves risk of loss.
Affiliate disclosure: This site may contain affiliate links to brokerage platforms. If you open an account through one of our links, we may earn a commission at no additional cost to you. Affiliate relationships do not influence our editorial content or stock coverage decisions.
Important Legal Disclaimer: This is for informational purposes only and is not financial, investment, or tax advice. Past performance is no guarantee of future results. We are not licensed advisors. For Swiss residents: This does not constitute a public offer under FINSA. For EU residents: Not MiFID II compliant advice. For US residents: Not SEC-registered advice. Always consult a qualified professional. Investing involves risk of loss.